As life science moves forward, someone has to provide stable and reliable solutions for identifying the right techniques and generating solid data from them.
Our primary focus it not on what we know, but how we can help our customers solve their problems.
Svar is a Swedish life science company that invent, develop and apply the best assay technology for drug development and clinical diagnostics, and establishes practical platforms for clinical routine testing.
We are delighted to announce several new products during 2020 within our key focus areas. These additions to our product portfolio support our already established products and reflect our continuing investment to support the drug development continuum.
Solutions based on the iLite reporter gene technology, modified and adapted for applications during the whole drug development continuum as well as for monitoring of biological drugs
Simple and objective functional and biomarker assays that can be used to explore every angle of complement system-involvement in a wide range of application areas
High quality total solutions for Calprotectin analysis. From fully automated systems, to home monitoring of patients with IBD
Specialist bioanalytical service laboratory centered on large molecules (biologics and biosimilars). CRO services according to GCP, GLP, and ISO 17025 with versatile solutions for the whole drug development continuum
A comprehensive range of individual tests and test panels, testing services and support for therapeutic drug monitoring that can help accelerate the drug development process
Our diagnostic service laboratory offer clinical testing specialized in autoimmunity assessment. Our request forms available for Autoimmune Diagnostics, Neurology testing and Monitoring of Biopharmaceuticals that list the test panels and individual markers currently available.
Please note that the forms can be downloaded, are interactive and can be filled out electronically.
”We provide life science customers high quality solutions, the best analytical technologies for drug development and clinical research and work to establish practical platforms for routine diagnosis”